These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37111519)

  • 1. Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.
    Golhen K; Buettcher M; Kost J; Huwyler J; Pfister M
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
    Comoglu T; Dilek Ozyilmaz E
    Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
    Chandrasekaran P; Kandasamy R
    AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orodispersible tablets for pediatric drug delivery: current challenges and recent advances.
    Wiedey R; Kokott M; Breitkreutz J
    Expert Opin Drug Deliv; 2021 Dec; 18(12):1873-1890. PubMed ID: 34822316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use.
    Preis M
    AAPS PharmSciTech; 2015 Apr; 16(2):234-41. PubMed ID: 25739913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
    Al-Khattawi A; Mohammed AR
    Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
    Strickley RG
    J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the Effects of Excipients in the Compounding of Amlodipine Besylate Orally Disintegrating Tablets.
    Azmi NHS; Ming LC; Uddin ABMH; Sarker ZI; Bin LK
    Int J Pharm Compd; 2022; 26(1):80-87. PubMed ID: 35081048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
    Cantor SL; Khan MA; Gupta A
    Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
    Thabet Y; Klingmann V; Breitkreutz J
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric drugs--a review of commercially available oral formulations.
    Strickley RG; Iwata Q; Wu S; Dahl TC
    J Pharm Sci; 2008 May; 97(5):1731-74. PubMed ID: 17823956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.
    Lou H; Liu M; Qu W; Hu Z; Brunson E; Johnson J; Almoazen H
    Drug Dev Ind Pharm; 2014 Jul; 40(7):910-8. PubMed ID: 23621768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Acceptability of an Orally Dispersible Tablet Formulation by Children.
    Wagner-Hattler L; Kiene K; Bielicki J; Pfister M; Puchkov M; Huwyler J
    Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33807822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Vural İ; Ünlü N
    Pharm Dev Technol; 2018 Jun; 23(5):488-495. PubMed ID: 28368673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets.
    Stirnimann T; Di Maiuta N; Gerard DE; Alles R; Huwyler J; Puchkov M
    Pharm Res; 2013 Jul; 30(7):1915-25. PubMed ID: 23604923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally disintegrating drug carriers for paediatric pharmacotherapy.
    Kean EA; Adeleke OA
    Eur J Pharm Sci; 2023 Mar; 182():106377. PubMed ID: 36634740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives.
    Ghourichay MP; Kiaie SH; Nokhodchi A; Javadzadeh Y
    Biomed Res Int; 2021; 2021():6618934. PubMed ID: 34977245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of medicines for children.
    Nunn T; Williams J
    Br J Clin Pharmacol; 2005 Jun; 59(6):674-6. PubMed ID: 15948931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2014 Apr; 103(4):1233-45. PubMed ID: 24532095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.